Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol
Therapeutic Area: Endocrinology Product Name: NE3107
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
NE3107, a new drug candidate in development for Alzheimer’s and Parkinson’s Diseases and other conditions, is an ERK inhibitor that selectively inhibits neuroinflammation and insulin resistance.
Lead Product(s): miRNA Based Therapy
Therapeutic Area: Endocrinology Product Name: RSVI-301
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Nexturn Bio
Deal Size: $5.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 30, 2021
RosVivo's new miRNA drug RSVI-301 significantly reduces injection frequency, showed a prolonged effect, and alleviated side effects such as GI dysmotility in animal studies. It is expected that RSVI-301 will become a first-in-class diabetic drug.